KIR2DL1
KIR2DL1是殺傷細胞免疫球蛋白樣受體家族的重要成員，全稱為殺傷細胞免疫球蛋白樣受體2DL1，也被稱作CD158a。KIR2DL1主要表達于自然殺傷細胞（NK細胞）表面，通過識別特定的人類白細胞抗原（HLA-C2亞型），向NK細胞傳遞抑制性信號，維持機體對健康細胞的免疫耐受。當靶細胞表面HLA-I類分子表達異常時，KIR2DL1的抑制作用減弱，NK細胞可被激活并殺傷靶細胞，這一機制在抗病毒感染和腫瘤免疫監(jiān)視中起關(guān)鍵作用。KIR2DL1基因多態(tài)性與白血病、艾滋病病程進展及妊娠期子癇前期等疾病密切相關(guān)。針對該受體的免疫療法成為研究熱點，例如通過單克隆抗體阻斷KIR2DL1與其配體結(jié)合，解除NK細胞活性抑制，已在多發(fā)性骨髓瘤和急性髓系白血病的臨床試驗中顯示出治療潛力。部分藥物如IPH2101已完成II期試驗，為腫瘤免疫治療提供了新策略。
熱銷產(chǎn)品
KIR2DL1 Recombinant Monoclonal Antibody (CSB-RA012352MA1HU)
驗證數(shù)據(jù)
IHC image of CSB-RA012352MA1HU diluted at 1：100 and staining in paraffin-embedded human lung tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-human polymer IgG labeled by HRP and visualized using 0.05% DAB.
KIR2DL1 Antibodies
KIR2DL1 for Homo sapiens (Human)
| 產(chǎn)品貨號 | 產(chǎn)品名稱 | 種屬反應性 | 應用類型 |
|---|---|---|---|
| CSB-PA006278 | KIR2DL1 Antibody | Human | WB, ELISA |
| CSB-PA012352LA01HU | KIR2DL1 Antibody | Human | ELISA, IHC, IF |
| CSB-PA012352LB01HU | KIR2DL1 Antibody, HRP conjugated | Human | ELISA |
| CSB-PA012352LC01HU | KIR2DL1 Antibody, FITC conjugated | Human | |
| CSB-PA012352LD01HU | KIR2DL1 Antibody, Biotin conjugated | Human | ELISA |
| CSB-RA012352MA1HU | KIR2DL1 Recombinant Monoclonal Antibody | Human | ELISA, IHC |
KIR2DL1 Proteins
KIR2DL1 Proteins for Homo sapiens (Human)
| 產(chǎn)品貨號 | 產(chǎn)品名稱 | 來源 |
|---|---|---|
| CSB-YP012352HU1 CSB-EP012352HU1 CSB-BP012352HU1 CSB-MP012352HU1 CSB-EP012352HU1-B |
Recombinant Human Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1), partial | Yeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli |
| CSB-CF012352HU | Recombinant Human Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) | in vitro E.coli expression system |
